Stockreport

RemeGen candidate Fast Track'd for lupus [Seeking Alpha]

GlaxoSmithKline PLC  (GSK) 
US:NYSE Investor Relations: gsk.com/en-gb/investors
PDF The FDA has signed off onFast Track statusRemeGenRC18Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the market [Read more]